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Abstract: An imbalance of angiogenesis contributes to many pathologies such as cancer, arthritis
and retinopathy, hence molecules that can modulate angiogenesis are of considerable therapeutic
importance. Despite many reports on the promising antiangiogenic properties of naturally occurring
flavonoids, no flavonoids have progressed to the clinic for this application. This systematic review
and meta-analysis therefore evaluates the antiangiogenic activities of a wide range of flavonoids and
is presented in two sections. The first part of the study (Systematic overview) included 402 articles
identified by searching articles published before May 2020 using ScienceDirect, PubMed and Web
of Science databases. From this initial search, different classes of flavonoids with antiangiogenic
activities, related pathologies and use of in vitro and/or in/ex vivo angiogenesis assays were identified.
In the second part (Meta-analysis), 25 studies concerning the antiangiogenic evaluation of flavonoids
using the in vivo chick chorioallantoic membrane (CAM) assay were included, following a targeted
search on articles published prior to June 2020. Meta-analysis of 15 out of the 25 eligible studies
showed concentration dependent antiangiogenic activity of six compared subclasses of flavonoids
with isoflavones, flavonols and flavones being the most active (64 to 80% reduction of blood
vessels at 100 µM). Furthermore, the key structural features required for the antiangiogenic activity of
flavonoids were derived from the pooled data in a structure activity relationship (SAR) study. All in all,
flavonoids are promising candidates for the development of antiangiogenic agents, however further
investigations are needed to determine the key structural features responsible for their activity.
Keywords: flavonoids; angiogenesis; inflammation; cancer; in-vivo angiogenesis; CAM assay; SAR
1. Introduction
Angiogenesis is the process of forming new blood vessels. Physiologically, angiogenesis is
pivotal for tissue growth and regeneration [1] which is beneficial for many processes including
embryogenesis and wound healing. Regulation of angiogenesis is complex and is maintained by the
balance between endogenous stimulators (e.g., vascular endothelial growth factor (VEGF), platelet
derived growth factors (PDGFs) and hypoxia-inducible factors (HIFs)), and inhibitors (e.g., angiostatin
and endostatin). Other body conditions also contribute to the regulation of angiogenesis under
physiological conditions. For example, certain metabolic demands such as the need for more oxygen
can induce VEGF secretion and angiogenesis in heart and brain tissues [2,3]. Since angiogenesis
affects many organs and tissues in the body, an imbalance in its regulation has been associated with
different pathologies [4]. For instance, cancer, rheumatoid arthritis and diabetic retinopathy feature
an upregulation of proangiogenic factors [5]. Conversely, if antiangiogenic factors were upregulated,
several cardiovascular diseases are more likely to happen [6]. The use of drugs like Bevacizumab
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(Avastin®, Genentech) and Aflibercept (Eylea®, Regeneron) for the treatment of cancer and ocular
diseases, emphasizes the imperative medicinal applications of antiangiogenic agents [7,8].
Flavonoids are widely distributed in fruits, vegetables and nuts. They are one of the most
important chemical classes of natural compounds showing various pharmacological profiles that include
anticancer [9–11], anti-inflammatory [12], cardioprotective [13] and neuroprotective activities [14].
The antiangiogenic activity of flavonoids has been extensively studied over the last two decades.
Several studies document the ability of flavonoids to inhibit the proliferation and migration of
endothelial cells by interfering with key angiogenesis signaling cascades such as the mitogen activated
protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Nevertheless, they can
inhibit the expression of major proangiogenic factors such as VEGF and matrix metalloproteinases
(MMPs) [2,7,15].
Researchers rely on different in vitro and in/ex vivo assays to quantitatively assess the effects of
chemical compounds on angiogenesis [16,17]. Each of these assays can probe one or more of the different
steps involved in the angiogenesis process such as cell proliferation, migration and tubulogenesis.
Despite considerable research concerning the antiangiogenic activities of flavonoids, to date they
have neither progressed to the market nor clinical trials for that purpose. Therefore, the aim of this
review is to systematically assess the antiangiogenic activities of flavonoids to provide greater insight
into their potential as therapeutic agents. This study is comprised of two parts: Section 1 provides a
systematic overview of the classes of flavonoids that have been investigated for their antiangiogenic
activities, along with a summary of the different in vitro and/or in/ex vivo angiogenesis assays that have
been used; Section 2 is a meta-analysis study of a quantitatively comparative subset of data, based on
the in vivo chick chorioallantoic membrane (CAM) assay, to statistically evaluate the antiangiogenic
effects of flavonoids.
2. Results
2.1. Section 1: Systematic Overview
2.1.1. Search Results
For Section 1 of the study, 3708 records were initially identified in three electronic databases
(1555 from ScienceDirect, 1984 from PubMed and 169 from Web of Science). Search results were then
limited to research articles, review articles, short communications and systematic reviews and the
remaining 3380 articles were subjected to title and abstract screening. 2556 records were found to be
irrelevant of the subject in focus or did not fulfill the inclusion criteria. After the removal of duplicates
(422), 402 articles were finally included in the qualitative analysis for Section 1 of this study (Figure 1).
2.1.2. Study Characteristics
The pool of studies included was classified with respect to: (a) flavonoid class (Figure 2),
(b) flavonoid name, (c) disease, (d) in vitro test and (e) in/ex vivo tests. Characteristics of the included
studies are summarized in Table 1 (flavonols are used as a representative example in Table 1 and
Table S1 contains similar data for all classes of flavonoids). A total of 402 research and review articles
were considered. All of the included articles reported angiogenesis related in vitro and/or in/ex vivo
assays for different classes of flavonoids.
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Table 1. Characteristics of the studies included in Section 1 for flavonols subclass (see Table S1 for all
9 subclasses).
Flavonol Disease In Vitro Tests In/Ex Vivo Tests Author, Year
Beturetol Angiogenesis CAM Hisanori Hattori, 2011 [18]
Casticin Cancer * Shanaya Ramchandani, 2020 [19]
Denticulatain Lung Cancer ZFM Da Song Yang, 2015 [20]
Dihydrokaempferide Angiogenesis CAM Hisanori Hattori, 2011 [18]
Fisetin
Cancer * Dharambir Kashyap, 2018 [21]
Cancer * Thamaraiselvan Rengarajan, 2016 [22]
Cancer * Deeba N.Syed, 2016 [23]
Cancer * Lall K. Rahul, 2016 [24]
Breast Cancer In Cheng Fang Tsai, 2018 [25]
Breast Cancer WH, In Xu Sun, 2018 [26]
Breast Cancer WH, In Mets in mice Jie Li, 2018 [27]
Cervical Cancer In Ruey Hwang Chou, 2013 [28]
Glioma In Chien Min Chen, 2015 [29]
Hepatic Cancer In Xiang Feng Liu, 2017 [30]
Leukemia In Anna Klimaszewska-Wis´niewska,2019 [31]
Lung Cancer WH, In Saba Tabasum, 2019 [32]
Lung Cancer WH, In, Ad Junjian Wang, 2018 [33]
Prostate Cancer WH, In, Ad Chi Sheng Chien, 2010 [34]
Renal Cancer In Yih Shou Hsieh, 2019 [35]
Retinopathy RbCN A M Joussen, 2000 [36]
Galangin
Hepatic Cancer * Dengyang Fang, 2019 [37]
Angiogenesis TF, Ad Jong Deog Kim, 2006 [38]
Glioma TF, In CAM, MD inmice Daliang Chen, 2019 [39]
Glioma In Deqiang Lei, 2018 [40]
Hepatic Cancer WH, In, Ad Shang Tao Chien, 2015 [41]
Ovarian Cancer TF CAM Haizhi Huang, 2015 [42]
Renal Cancer WH, In Jingyi Cao, 2016 [43]
Renal Cancer In Yun Zhu, 2018 [44]
Gossypin Gastric Cancer In Wang Li, 2019 [45]
Herbacetin Melanoma In Lei Li, 2019 [46]
Hyperoside Arthritis WH, In CIAM in mice Xiang Nan Jin, 2016 [47]
Icariin
Bone disease * Xin Zhang, 2014 [48]
Cancer * Meixia Chen, 2016 [49]
Angiogenesis TF, In RAR Byung Hee Chung, 2008 [50]
Esophageal Cancer In Zhen Fang Gu, 2017 [51]
Ovarian Cancer WH Pengzhen Wang, 2019 [52]
Wound healing EWM in rats Wangkheirakpam Ramdas Singh,2019 [53]
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Flavonol Disease In Vitro Tests In/Ex Vivo Tests Author, Year
Icariside
Cancer * Meixia Chen, 2016 [49]
Glioma WH, In Kai Quan, 2017 [54]
Isoviolanthin Hepatic Cancer WH, In Shangping Xing, 2018 [55]
Isosakuranetin Angiogenesis CAM Hisanori Hattori, 2011 [18]
Kaempferol
Cancer * Allen Y. Chen, 2013 [56]
Cancer * Dharambir Kashyap, 2017 [57]
Angiogenesis WH, TB, In Hsien Kuo Chin, 2018 [58]
Angiogenesis WH, TB ZFM Fang Liang, 2015 [59]
Angiogenesis CAM Shigenori Kumazawa, 2013 [60]
Angiogenesis TF, Ad Jong Deog Kim, 2006 [38]
Diabetes EWM in rats Yusuf Özay, 2019 [61]
Glioma WH Vivek Sharma, 2007 [62]
Glioma In Mets in mice S.C. Shen, 2006 [63]
Hepatic Cancer WH, In Mets in mice Youyou Qin, 2015 [64]
Hepatic Cancer In Genglong Zhu, 2018 [65]
Lung Cancer WH, In Eunji Jo, 2015 [66]
Medulloblastoma Ad David Labbé, 2009 [67]
Oral Cancer In Chiao Wen Lin, 2013 [68]
Osteosarcoma WH, In, Ad Hui Jye Chen, 2013 [69]
Ovarian Cancer CAM Haitao Luo, 2009 [70]
Pancreatic Cancer In Jungwhoi Lee, 2016 [71]
Renal Cancer WH, In Mets in mice Tung Wei Hung, 2017 [72]
Retinal
Vascularization WH, In Hsiang Wen Chien, 2019 [73]
Kaempferol-3-O-[(6-
caffeoyl)-β-
glucopyranosyl (1→3)
α-rhamnopyranoside]-7-
O-α-rhamnopyranoside
Angiogenesis WH Marco Clericuzio, 2012 [74]
Kaempferide Angiogenesis CAM Hisanori Hattori, 2011 [18]
Morin
Arthritis WH, TB CIAM in rats Ni Zeng, 2015 [75]
Arthritis WH, TB CIAM in rats Mengfan Yue, 2018 [76]
Leukemia Ad Nagaja Capitani, 2019 [77]
Melanoma WH Hua Wen Li, 2016 [78]
Myricetin
Melanoma * Nam Joo Kang, 2011 [79]
Angiogenesis TF, Ad Jong Deog Kim, 2006 [38]
Breast Cancer In CAM, MD inmice, RAR Zhiqing Zhou, 2019 [80]
Breast Cancer WH, In, Ad Mets in mice Yingqian Ci, 2018 [81]
Glioma WH, In Wen Ta Chiu, 2010 [82]
Hepatic Cancer In Noriko Yamada, 2020 [83]
Hepatic Cancer WH, In Hongxin Ma, 2019 [84]
Lung Cancer WH, In, Ad Yuan Wei Shih, 2009 [85]
Medullobalstoma In, Ad David Labbé, 2009 [67]
Ovarian Cancer TF CAM Haizhi Huang, 2015 [42]
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Table 1. Cont.
Flavonol Disease In Vitro Tests In/Ex Vivo Tests Author, Year
Quercetin
Breast Cancer * Maryam Ezzati, 2020 [86]
Cancer * Si-min Tang, 2020 [87]
Cancer * Dharambir Kashyap, 2016 [88]
Colorectal Cancer * Saber G. Darband, 2018 [89]
Angiogenesis WH, In Nu Ry Song, 2014 [90]
Angiogenesis WH, TB ZFM Chen Lin, 2012 [91]
Angiogenesis TF, Ad Jong Deog Kim, 2006 [38]
Bladder Cancer WH, In Yu Hsiang Lee, 2019 [92]
Breast Cancer WH Divyashree Ravishankar, 2015 [93]
Breast Cancer MD in mice Xin Zhao, 2016 [94]
Breast Cancer CAM Soo Jin Oh, 2010 [95]
Breast Cancer WH, In Asha Srinivasan, 2016 [96]
Breast Cancer WH, In Cheng Wei Lin, 2008 [97]
Breast Cancer In Amilcar Rivera Rivera, 2016 [98]
Cancer TF ZFM Daxian Zhao, 2014 [99]
Cancer TF, In CAM Wen Fu Tan, 2003 [100]
Cancer MD in mice Xiangpei Zhao, 2012 [101]
Cancer WH, In Lung Ta Lee, 2004 [102]
Cancer WH Dong Eun Lee, 2013 [103]
Colorectal Cancer WH, In Mets in mice Ji Ye Kee, 2016 [104]
Glioma WH Hong Chao Pan, 2015 [105]
Glioma WH, In Wen Ta Chiu, 2010 [82]
Glioma WH, In Yue Liu, 2017 [106]
Glioma In Jonathan Michaud-Levesque, 2012[107]
Glioma WH Alessandra Bispo da Silva, 2020 [108]
Glioma WH, TB, In Yue Liu, 2017 [109]
Hepatic Cancer In Noriko Yamada, 2020 [83]
Hepatic Cancer WH, In Jun Lu, 2018 [110]
Lung Cancer WH Anna Klimaszewska-Wis´niewska,2017 [111]
Lung Cancer In Tzu Chin Wu, 2018 [112]
Lung Cancer In Yo Chuen Lin, 2013 [113]
Medulloblastoma In, Ad David Labbé, 2009 [67]
Melanoma In Mun Kyung Hwang, 2009 [114]
Melanoma In Hui Hui Cao, 2015 [115]
Melanoma WH, In Mets in mice Hui Hui Cao, 2014 [116]
Oral Cancer In Junfang Zhao, 2019 [117]
Osteoblasts In Tae Wook Nam, 2008 [118]
Osteosarcoma WH, In, Ad Shenglong Li, 2019 [119]
Osteosarcoma WH, In Mets in mice Haifeng Lan, 2017 [120]
Osteosarcoma WH, Ad Kersten Berndt, 2013 [121]
Pancreatic Cancer WH, In Ying Tang Huang, 2005 [122]
Pancreatic Cancer WH, In Yu Dinglai 2017 [123]
Prostate Cancer WH, In Firdous Ahmad Bhat, 2014 [124]
Prostate Cancer TF, In MD in mice Feiya Yang, 2016 [125]
Retinoblastoma In Wei Song, 2017 [126]
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Table 1. Cont.
Flavonol Disease In Vitro Tests In/Ex Vivo Tests Author, Year
Quercetin-3-O-[(6-
caffeoyl)-β-
glucopyranosyl(1→3)
α-rhamnopyranoside]-7-
O-α-rhamnopyranoside
Angiogenesis WH Marco Clericuzio, 2012 [74]
Rutin
Angiogenesis CAM César Muñoz Camero, 2018 [127]
Angiogenesis CAM Shigenori Kumazawa, 2013 [60]
Cancer WH, In, Ad Mohamed ben Sghaier, 2016 [128]
Glioma WH Alessandra Bispo da Silva, 2020 [108]
Neuroblastoma WH, In Hongyan Chen, 2013 [129]
* Review article; TB, Tube Formation; WH, Wound Healing; In, Invasion; Ad, Adhesion; Mets, Metastasis; CAM,
Chick Chorioallantoic Membrane; MPA, Matrigel Plug Assay; RAR, Rat Aortic Ring; EWM, Excision Wound Model;
SF, Skin Flap; RRN, Rat Retinal Neovascularization; MAR, Mice Aortic Ring; MD, Microvessel Density; MRN, Mice
Retinal Neovascularization; MCN, Mice Corneal Neovascularization; RbCN, Rabbit Corneal Neovascularization;
ZFM, Zebra Fish Model; RCN, Rat Corneal Neovascularization; CIAM, Collagen Induced Arthritis Model; DASM,
Dorsal Air Sac Model; IWM, Incision Wound Model.
2.1.3. Data Analysis
The majority of articles (332, 82%) focused on the implications of angiogenesis on cancer growth
and metastasis. 7% of the articles studied antiangiogenic effects of flavonoids on other diseases such
as diabetes, bone and eye diseases, whilst 11% focused on the antiangiogenic activity of flavonoids
without application to a specific pathology (Figure 3a). A profiling of the studies retrieved with respect
to chemical class of flavonoids is shown in Figure 3b.
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Figure 4 summarizes the types of in vitro and in vivo assays that were utilized in the studies.
From a pool of 342 research articles included in this study, 152 articles (44%) reported a combination of
in vitro and in/ex vivo assays in their studies. The percentage of research articles that depended only
on in/ex vivo tests to evaluate antiangiogenic activity of flavonoids were comparatively low compared
to those conducting only in vitro assays (3% vs. 53%, respectively).
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2.2. Section 2: Meta-Analysis
2.2.1. Search Results
The second ubset search, w ich s the basi of the -analy is forming Secti n 2 of this study,
followed the same general methodology as detailed in the initial overview. 960 records were identified
from four electronic databases (381 from ScienceDirect, 496 from PubMed, 65 from Web of Science and
18 from Google Scholar). 25 research articles were finally included in the quantitative analysis after the
sequential steps of screening and sifting, as shown in Figure 5.
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2.2.2. Study Characteristics
The main study characteristics of the research articles included in Section 2 for the meta-analysis
are summarized in Table 2 by study name.
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Table 2. Characteristics of the studies included in Section 2.
Author, Year Flavonoid AngiogenesisPromoter Cell Line Concentration
Time, Duration of
Treatment
Results
Representation n
Soo Jin Oh, 2010 [95] Quercetin NA TAMR-MCF-7 3, 10, 30 µM NA Number ofbranches 5 to 7
Chiu-Mei Lin, 2006 [130] Wogonin LPS(1µg/mL) NA
10−5, 10−6, 10−7,
10−8 M 10th day, 48 h
Percentage of
vascular counts
(%)
3
Ling-Zhi Liu, 2011 [131] Acacetin NA OVCAR-3 10 µM 9th day, 4 days Relativeangiogenesis 5
Kai Zhao, 2018 [132] Wogonin, LW-215 NA NA
Wogonin:
80 ng/CAM,
LW-215: 2, 4,
8 ng/CAM
10th day, 48 h
The number of
new vessels (% of
control)
3
Haizhi Huang, 2015 [42] Galangin, myricetin NA OVCAR-3 G: 40 µM, M:20 µM 9th day, 5 days Blood vessels (%) 6
Olga Viegas, 2019 [133] Cyanidin, C-3-O-glucoside, delphinidin,D-3-O-glucoside NA NA
20, 40, 80, 100,
200 µM 11th day, 48 h % of control 5
Wen-fu Tan, 2003 [100] Quercetin NA NA 25, 50,100 nmol/10µL/CAM 10th day, 48 h
Microscopic
pictures 10
Rajesh Gacche, 2010 [134] Flavone, 3/5/6/7/-Hydroxy flavone NA NA 10, 50, 100 µM 10th day, 48 h
Antiangiogenic
activity (%) of
selected flavonoids
8
R.N. Gacche, 2011 [135]
3, 6-DHF, 3, 7-DHF, 5, 7-DHF, apigenin,
genistein, kaempferol, luteolin, fisetin,
rutin, quercetin
NA NA
10, 50, 100 µM in
0.05%
DMSO/20µL/CAM
10th day, 48 h
Antiangiogenic
activity (%) of
selected flavonoids
8
R.N. Gacche, 2015 [136]
4′-Methoxy flavone,
3-Hydroxy-7-methoxy flavone,
Formononetin, Biochanin-A, Diosmin,
Hesperitin, Hesperidin, 2′-Hydroxy
flavanone, 4′-Hydroxy flavanone,
7-Hydroxy flavanone, Myricetin,
Taxifolin, Silibinin, Silymarin,
Naringenin, Naringin, Catechin
NA NA
10, 50, 100 µM in
0.05%
DMSO/20µL/CAM
10th day, 48 h
Antiangiogenic
activity (%) of
selected flavonoids
8
Yan Chen, 2010 [137] LYG-202 NA NA 2.4, 12, 60 ng/CAM 10th day, 48 h
Percentage of
vascular counts (%
of control)
10
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Table 2. Cont.
Author, Year Flavonoid AngiogenesisPromoter Cell Line Concentration
Time, Duration of
Treatment
Results
Representation n
Hisanori Hattori, 2011 [18] Beturetol, isosakuranetin NA NA 300 ng/CAM 5th day, 7 days
Inhibition % of
angiogenesis at
300 ng/CAM.
10
Yujie Huang, 2019 [138] Wogonoside NA MDA-MB-231,MDA-MB-468
50, 100,
200 ng/CAM 10th day, 48 h
Number of new
vessels (% cells) 3
Yan Chen, 2009 [139] Wogonoside LPS(1µg/mL) NA
1.5, 15,
150 ng/CAM 10th day, 48 h
Number of vessels
(% of LPS) 10
Xiaobo Li, 2017 [140] Luteolin Gas6 (300ng/mL) NA 10, 20 µM 6th day, 48 h
Relative vascular
density (% of
control)
3
Siva Prasad Panda, 2019 [141] TMF NA EAT 10, 17, 25 µg/mL 5th day, 11 days Microscopicpictures 5
Yujie Huang, 2016 [142] Wogonoside NA MCF-7 50, 100,200 ng/CAM 10th day, 48 h
Number of new
vessels (% MCF-7) 3
Tariq A. Bhat, 2013 [143] Acacetin NA NA 50 µM 6th day, (every48 h for 8 days)
% capillary
formation
5 independent
areas on CAMs
for each
treatment
Jing Fang, 2007 [144] Apigenin NA OVCAR-3,PC-3
OVCAR-3: 7.5,
15 µM,
PC-3: 10, 20 µM
9th day, 4 days
Quantification of
blood vessels on
the CAM
8
Jianchu Chen, 2015 [145] Nobiletin NA A2780 20 µM 9th day, 5 days Blood vessel count 10
Poyil Pratheeshkumar, 2012 [146] Luteolin NA NA 20, 40 µM 8th day, 48 h Relative vasculardensity 3
Chiu-Mei Lin, 2006 [147] Wogonin IL-6 (10ng/mL) NA
10−5, 10−6, 10−7,
10−8 M 10th day, 48 h
Percentage of
vascular count (%) 3
Dongqing Zhu, 2016 [148] Baicalin, baicalein NA NA
0.5, 2, 10, 50 µg/mL
and 0.2, 1,
5 mg/mL
7.5th day, 48 h Number of newblood vessels 30
Haitao Luo, 2009 [70] Kaempferol NA OVCAR-3 20 µM 9th day, 5 days Blood vessel count 5
Laure Favot, 2003 [149] Delphinidin NA NA 2, 10, 25, 50 µg 8th day, 48 h Microscopicpictures 5
n = number of CAMs used in each experiment; NA, Not available; DHF, Dihydroxyflavone; TMF, Trimethoxyflavonoid; TMAR, Tamoxifen breast cancer resistant cell line; MCF-7, Breast
cancer cell line; LPS, Lipopolysaccharide; OVCAR-3, Ovarian cancer cell line; MDA-MB-231, MDA-MB-468, Triple negative breast cancer cell lines; Gas6, Growth arrest specific 6; EAT,
Mouse breast carcinoma (Ehrlich-Lettre Ascites); PC-3, Prostate cancer cell line; A2780, ovarian cancer cell line; IL-6, Interleukin 6.
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2.2.3. Meta-Analysis (Antiangiogenic Effect of Flavonoids on CAMs)
25 studies reporting the CAM assay for the in vivo evaluation of flavonoids were eligible for
the meta-analysis. The number of blood vessels relative to the control was used as the outcome
measure, the lower the ratio the higher the antiangiogenic activity. The studies were grouped into
3 sub-sets based on the controls used. In the first set (12 studies), the normal vasculature of the
CAM was used as a control without any interventions that would induce angiogenesis. The second
and third sets, however, tested the antiangiogenic activity of flavonoids on CAMs with abnormal
angiogenesis using either proangiogenic factors for set 2 (4 studies) or cancer cell lines for set 3
(9 studies). 10 studies [18,95,100,132,137,139–141,145,149] out of the 25 eligible studies were not
included in any of the conducted meta-analyses as they failed to report the required data outcomes or
did not fit under any particular subgroup.
Set 1: Antiangiogenic effect of flavonoids under normal conditions
To ensure consistency in our comparison, for the meta-analysis of set 1, the concentrations were
grouped into three ranges i.e., low (10–20 µM), medium (40–50 µM) and high (100 µM). Flavonoids
were sub grouped based on their chemical class as shown in Figure 6. Pooled results indicate that all
subclasses, except for anthocyanidines, demonstrate concentration dependent antiangiogenic activity
expressed as a reduction in the number of blood vessels in a CAM. For the flavonols subgroup,
for instance, the overall means ratios (summary estimates of antiangiogenic activity of a subgroup
of flavonoids relative to control) were 0.74 (95%CI: 0.69, 0.79; p-value < 0.00001), 0.50 (95%CI: 0.46,
0.56; p-value < 0.00001) and 0.26 (95%CI: 0.19, 0.35; p-value < 0.00001) for the low, mid and high
concentrations, respectively. On the other hand, the anthocyanidines subgroup exhibited only a minor
overall reduction of 18% at the highest concentration and a slightly proangiogenic effect (overall means
ratio: 1.07; 95%CI: 0.86, 1.33; p-value: 0.53) at 20 µM.
In addition to the forest plot analysis that gives a general idea about the overall in vivo
antiangiogenic activity of flavonoids and identifies trends of activity among the different subclasses,
some structure activity relationship (SAR) conclusions were drawn from the pooled results (Figure 7).
First, there was no correlation between the number of hydroxyl groups and antiangiogenic activity.
However, the position of the hydroxyl groups appeared to be of importance as most of the highly
active flavonoids had hydroxyl groups at positions 3, 5 and 7 and/or 4′ (e.g., as demonstrated for 3-OH
flavone, acacetin, biochanin A, apigenin, silibinin and kaempferol). The 7-OH group can be considered
to be of greatest importance for activity since 7-OH flavone showed higher activity in the low and
medium concentrations compared to the 5-OH analogue. Absence of the 3-OH group caused up to a
14% decrease in activity at the 50 and 100 µM concentrations, as demonstrated, for example, for 3-OH
flavone vs. flavone, kaempferol vs. apigenin and 3,7-diOH flavone vs. 7-OH flavone. This was also
true for quercetin vs. luteolin but with only a trivial drop of activity of 1 to 2%. However, this was not
the case for 3,6-diOH flavone vs. 6-OH flavone where removal of the 3-OH group slightly increased
the activity by 1 to 5% at the mid and high concentrations.
Secondly, unsaturation of the C2 and C3 bond is a common feature of most of the highly active
flavonoids and is important for activity. 7-OH flavone and 7-OH flavanone are two good examples
that exemplify this, as demonstrated by a reduction of the number of vessels: 27%, 32% and 52% for
7-OH flavone and 10%, 22% and 39% for 7-OH flavanone at 10 µM, 50 µM, and 100 µM, respectively.
Third, there are examples of where the presence of a methoxy group at position 4′ increases
activity (e.g., biochanin A, diosmin and formononetin). However, the presence of a methoxy group
at C7 caused a decrease in the activity when compared to the unsubstituted analogue (ie for the
3-OH flavone vs. 3-OH-7-OCH3 flavone, reduction of number of vessels: 35% and 20% at 10 µM,
64% and 42% at 50 µM, 79% and 69% at 100 µM, respectively). On the other hand, conversion of the
7-OH group in 3,7-diOH flavone to a 7-OCH3 group in 3-OH-7-OCH3 flavone slightly improved the
activity (reduction of number of vessels) from 18% to 20% at 10 µM and from 63% to 69% at 100 µM,
respectively. Finally, glycosylation at positions 3 or 7 showed neither a pronounced nor a consistent
effect on the antiangiogenic activity of flavonoids. While a decrease in activity was observed with
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quercetin vs. rutin, hesperitin vs. hesperidin and cyanidin vs. cyanidin-3-O-glucoside, an increase was
observed in the cases of naringin vs. naringenin and delphinidin vs. delphinidin-3-O-glucoside.
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T e documented reduction in the number of CAM blood vessels by wogonin was shown to be dos
dependent in b th c ses but more prominent in the case of IL-6 i uced angiogenesis ( 5% as opposed to
38% in the case of LPS induced angiogenesis at 100 µM) (Figure 8). The authors also probed the possible
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in vitro techniques such as western blotting polymerase chain reaction (PCR) i which both LPS and
IL-6 resulted in an upregulation of the IL-6/IL-6R athway [130,147]. Although wogonin attenuated the
IL-6/IL-6R pathway and levels of VEGF in both cases, it exhibite different expression f downstream
vascular e dot elial gr wth factor receptors (VEGFRs). O ly VEGFR2 expression was downregulated
with wogonin LPS-induced angiogenesis inhibition as opposed to VEGFR1 downregulation with IL-6
induced a giogenesis inhibition. This data needs further investigation in order t understand why
these two similar mechanisms lead to the downregulation of two differe t downstream receptors
(VGFR2 and VEGFR1) and to address the impact of this on the antiangiogenic potency. Inhibition
of LPS-induced angiogenesis was also reported for wogonoside, which is the 7-glucuronic acid of
wogonin, by Chen et al. [139] 150 ng/CAM of wogonoside reduced neo-vascularization of CAMs by
43%. Additionally, wogonoside downregulated mammalian toll-like receptor (TLR4), extracellular
signal-regulated kinase (ERK1/2) and p38MAPK in a western blotting assay [139].
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Since angiogenesis plays a vital role in tumor growth and metastasis, several studies have
focused on the antiangiogenic evaluation of promising cytotoxic agents. Figure 9 shows the estimated
antiangiogenic effect of the 4 flavonoids apigenin, myricetin, acacetin and keampferol on the ovarian
cancer cell line (OVCAR-3) at 10–20 µM. The reduction in the number of CAM blood vessels ranged
from 30 to 60% with an overall summary outcome of 0.35 (95%CI: 0.27, 0.45; p-value < 0.00001).
HIFα and VEGF were significantly downregulated, as evidenced by immunoblotting analysis of
CAM OVCAR-3 tissues that were treated with apigenin or acacetin [131,144]. The antiangiogenic
activity of the flavone wogonoside was evaluated on the estrogen receptor positive (MCF-7) and two
triple negative breast (MDA-MB-231 and MDA-MB-468) cancer cell lines by Huang et al. [138,142].
At 50 ng/CAM, wogonoside’s effect on the 3 cell lines was not prominent (Figure 10). However,
a 55% reduction of the number of blood vessels was observed at 100 ng/CAM for the MDA-MB-468
cell line. A two-fold increase in the concentration of wogonoside to 200 ng/CAM did not, however,
result in an increased antiangiogenic effect on the same cell line. On the other hand, reduction of the
neo-vascularization for the MDA-MB-231 cell line increased from 32% to 77% upon increasing the
concentration from 100 to 200 ng/CAM. Huang et al. demonstrated the ability of wogonoside to target
the Hedgehog signaling pathway, which is upregulated in triple negative breast cancer, in MDA-MB-231
and MDA-MB-468 cell lines [138]. Expression of the Hedgehog downstream transmembrane protein
smoothened (SMO) and glioma-associated oncogene homolog protein (Gli), is significantly increased
in triple negative breast cancer [150] leading to an elevation in VEGF levels [151]. According to Huang
and his colleagues, wogonoside promoted SMO degradation and inhibited Gli1 activity as well as
expression of VEGF [138].Molecules 2020, 25, x FOR PEER REVIEW 19 of 34 
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Figure 9. Forest plot of means ratio and 95% confidence interval (CI) of number of blood vessels relative
to control of flavonoids on OVCAR-3 cell lines.
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2.2.4. Sensitivity Analysis
The high heterogeneity (I2 > 80%) observed for all subgroups in the generated forest plots, except
for the anthocyanidines subgroup at the mi and high concentra ions analyses (I2 = 0% and 40%,
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respectively), was expected given that each class included different flavonoid molecules. In that context,
a sensitivity analysis was conducted by a leave-one-out strategy to assess the robustness of the results
and determine the contribution of each flavonoid to heterogeneity. Overall, the results showed good
robustness and the overall summary estimates did not show significant changes upon the systematic
removal of individual studies (Tables S2–S4). This was the case in all subgroups with the exception of
the flavanol subgroup which showed some difference in the overall summary at all concentrations.
At the 40–50 µM range for instance, the overall pooled means ratio changed from 0.53 (95%CI: 0.27, 1.02,
I2 = 100%) to 0.74 (95%CI: 0.73, 0.76, NA) and 0.38 (95%CI: 0.37, 0.39, NA) upon removal of the Gacche
2015 (Silibinin) and Gacche 2015 (Taxifolin) flavonoids, respectively (Table S3). This indicates that
data provided on the flavanols subgroup is not sufficient to draw meaningful conclusions. Likewise,
heterogeneity (I2) of the subgroups totals did not show significant change, with very few exceptions,
upon implementation of the leave-one-out strategy (Tables S2–S4). This might be due to the fact that
most of the flavonoids in a single subgroup belong to the same study, consequently, there are no
differences in their experimental designs. In that case heterogeneity is believed to be either of clinical
or statistical origin.
3. Discussion
Flavonoids have been reported to modulate several angiogenic factors and cascades in either a
proangiogenic or an antiangiogenic manner which is postulated to be dose dependent [2,148]. A good
illustration of this dual effect is demonstrated by the flavone baicalin; low doses were reported to
stimulate angiogenesis [152] whilst high doses showed an inhibitory effect [153]. Due to the emerging
importance of the use of angiogenesis modulators in the treatment of various pathological conditions
including cancer, diabetes, bone, eye, cardiovascular and neurological disorders, the identification of
flavonoids altering angiogenesis has gained new significance [2,154]. To the best of our knowledge,
no systematic reviews have been conducted to quantitatively assess the antiangiogenic effects of
flavonoids, despite the potential of such a study to have a positive impact on the treatment of serious
health issues like cancer and rheumatoid arthritis. Given the breadth of the literature related to the
antiangiogenic effects of flavonoids, a systematic search of the literature was initially conducted in
this research program to identify (a) the extent to which angiogenesis modulation effects had been
proposed for flavonoids and (b) the most widely used in vitro and in/ex vivo assays to determine the
antiangiogenic activities of flavonoids.
Various study designs have been used in the literature to report on the antiangiogenic activity
of chemical compounds. There are a number of comprehensive reviews in the literature comparing
the different available angiogenesis assay models [16,17,155,156]. Although in vitro studies are less
expensive and quicker to perform than in vivo studies, the results do not always convert into the same
effect, in vivo. In vitro assays usually focus on monitoring the individual steps of angiogenesis such as
migration or proliferation of endothelial cells rather than the collective formation of new tube-like
structures [16]. In vivo assays offer the considerable advantage of mimicking more closely the body’s
physiological conditions which is particularly important in angiogenic studies due to the complex
nature of the process. While in vivo angiogenesis assays can be more informative, they present some
cost, time and experimental design limitations. Inflammation resulting from the trauma that is caused
by some assays, for instance, can stimulate several proangiogenic factors which compromise the
sensitivity and specificity of the results [17]. Hence, it is recommended that a combination of in vitro
and in vivo assays is used to provide consistent and complementary results. In relation to this, 44% of
the research articles included in the conducted preliminary search reported a combination of in vitro
and in/ex vivo assays.
Herein, a meta-analysis study was carried out in order to quantitatively evaluate the antiangiogenic
effects of flavonoids. Only articles implementing the CAM assay in their study design were included.
This is because the CAM assay is currently the most widely used in vivo angiogenic assay and,
as such, it allows a comparison across different flavonoid types and offers many advantages over
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other angiogenic assays [157–159]. For instance, it is fairly simple, inexpensive, suitable for large scale
screening and also offers the important advantage of expressing almost all of the known angiogenic
factors [17,156]. Set-up of the assay is briefly as follows: fertilized chicken eggs are incubated at 37 ◦C
for 3 days, a small hole is made in the egg shell to remove some of the albumin in order to facilitate
detachment of the CAM from the shell. Compounds under investigation are added to approximately 5
to 10 day old chicks on specific carriers, such as matrigel or sterile filter/plastic discs, through a small
window cut in the egg shell. After 48 to 72 h, existing blood vessels or tubules can be visualized and
evaluated by light or electron microscopy [17,156]. Nevertheless, the CAM test comes with certain
limitations such as sensitivity to oxygen tension and difficulty of visualization of newly formed vessels
due to the presence of pre-existing ones [157].
Meta-analysis of results of the antiangiogenic evaluation of flavonoids via the in vivo CAM
assay showed increasing activities with increasing concentrations. The evaluated flavonoids also
demonstrated antiangiogenic activities of varying potencies. In light of this, results were inspected
to gain some insights on the SAR of antiangiogenic activity of flavonoids (Figure 7). Although SARs
of chemical compounds change based on the sought pharmacological activity, there are some
common structural features of flavonoids that are recognized as important for activity [160].
Combination of the C2=C3 double bond and a 4-C=O is favorable for the antiviral/bacterial [161],
anticancer [162,163], cardioprotective [164], anti-inflammatory [165], and antioxidant [164] activities
of flavonoids. This conjugation maintains the planarity of the molecule and helps with the electron
delocalization between rings A and C which is important for interaction with several targets [160].
Similarly, the 5, 7 di-OH is important for many of the biological activities of flavonoids [164,166–168].
This can be explained by the fact that flavonoids exert different pharmacological activities that have
mutual and/or overlapping mechanisms. For example, the antioxidant activity of flavonoids contributes
to their anti-inflammatory activity and both contribute to their anticancer activity. Moreover, several
targets in the body have structurally similar binding sites and this is a phenomenon that is partially
responsible for drug promiscuity or polypharmacology (binding of a drug to multiple targets). This was,
in fact, observed for binding of the flavonoid quercetin with phosphatidylinositol 4,5-bisphosphate
3-kinase (PI3KCG) and the serine/threonine proto oncogene, PIM1 kinase [169].
With respect to the antiangiogenic activity of flavonoids, limited SAR studies have been reported.
Lam et al. tested the antiangiogenic activity of a number of polymethoxylated flavonoids in vitro and
in vivo [170]. The authors concluded that methylation of C5, C6, C7 and/or C4′ OH groups increased
the activity which is in agreement with Ravishankar et al. [93] who reported the in vitro antiangiogenic
activity of a number of quercetin and luteolin derivatives. Our results also suggest that the presence of
a 4′-OCH3 increases the antiangiogenic activity. Despite this, there were some discrepancies between
the aforementioned SAR conclusions. In this SAR analysis we showed that the presence of a 3-OH
group enhanced the antiangiogenic activity, which is in contrast to the report from Ravishankar et al.
that noted that the same 3-OH caused a drop in the activity yet methylation of that OH increased
the activity [93]. A study by Lam et al. reported that glycosylation at C7 dramatically decreased
the activity [170] while our study showed such modification to cause a minor or no decrease in the
activity and even a slight increase in some cases. These inconsistencies are likely to be a result of the
different experimental methodologies and flavonoid concentrations used in each study. Additionally,
the different evaluated flavonoids might exert their antiangiogenic activities by binding to different
targets that require different structural features. This highlights the need for larger scale studies to more
fully probe the antiangiogenic SAR of flavonoids taking in consideration the employed mechanisms
of action.
Since the relation between inflammation and angiogenesis is well established and many flavonoids
possess anti-inflammatory activities, several studies assessed the antiangiogenic effects of flavonoids
on inflammation-induced angiogenesis. Inflammatory cells like T-lymphocytes and macrophages
secrete cytokines that can control the survival, proliferation, activation and migration of endothelial
cells [171,172]. Endothelial cells can additionally produce several cytokines and chemokines
Molecules 2020, 25, 4712 19 of 31
themselves [173]. Flavonoids such as baicalin, quercetin and kaempferol caused a reduction in
both inflammatory and angiogenic markers in cultured macrophages and human umbilical vein
endothelial cells (HUVECs) [174,175].
Bacterial infections also trigger angiogenesis through inflammatory pathways. In that context,
binding of LPS to the TLR4 receptor located on the surface of endothelial cells leads to upregulation
of ERK1/2 and p38MAPK pathways and increases production of pro-inflammatory cytokines like
IL-6 [176,177]. Pro-inflammatory cytokines like IL-6 and tumor necrosis factor α (TNFα) can interact
with VEGF expression and promote angiogenesis [178,179]. The flavone, wogonin, and its glucoside,
wogonoside, showed promising antiangiogenic activity against LPS induced angiogenesis [130].
Wogonin also inhibited IL-6 induced angiogenesis in a concentration dependent manner where it was
reported to downregulate VEGFR1 not VEGFR2 genetic expression [147]. While VEGR2 is the main
receptor for VEGF and is downregulated by many flavonoids [91,180], VEGFR1‘s role in angiogenesis
is still not fully understood and needs further investigation.
As mentioned earlier, cancer is one of the most serious pathologies related to angiogenesis. When
cells grow malignantly beyond a certain size, they need more vascularization to receive oxygen and
nutrients i.e., tumors depend on angiogenesis to grow above a certain limit, and to metastasize [181].
The tumor vasculature is characterized by an imbalance between pro and anti-angiogenic factors where
several angiogenic stimulators like VEGF and HIF are overexpressed. The HIFs are major regulators of
angiogenesis and orchestrate many of the steps involved [182]. Under physiological conditions, HIFs
are released in response to low oxygen levels in the blood (hypoxia) and stimulate angiogenesis at
various levels from endothelial cell proliferation to activating the transcription of angiogenic genes like
VEGF and platelet derived growth factor (PDGF). During malignancy, HIF dependent angiogenesis is
activated either in response to the predominant hypoxic environment or by the genetic transformations
caused by cancer. Flavonoids can downregulate HIFα and VEGF in different cancer cell lines such as
OVCAR-3, A2780, MCF-7 and PC-3 [42,70,95,131,144,145]. Many studies have also reported the ability
of the flavonoids 3-hydroxy flavone, hesperidin, apigenin, fisetin and many others to reduce tumor
size, capillary density and metastasis of different cancers, such as osteosarcoma, melanoma, lung and
breast cancers, in xenograft mice [26,183–187].
Although this meta-analysis demonstrated the overall promising in vivo antiangiogenic activity
of flavonoids whether in normal, inflammatory or tumor conditions, there were some limitations to
the study. First, the standard forms and guidelines used in a systematic analysis are only applicable for
clinical or animal trials. Consequently, the quality of the retrieved studies and publication bias were not
taken into account here, as this would be methodologically inappropriate. As such, large scale animal
studies and meta-analyses evaluating the antiangiogenic activity of flavonoids are much needed in the
future to provide more definitive conclusions about the role of flavonoids in angiogenesis.
Second, despite subgrouping flavonoids based on their chemical class and using the random effects
model, heterogeneity remained high in this study. There are three types of heterogeneity as defined by
the Cochrane handbook for systematic reviews, (i) clinical: differences in participants, interventions or
outcomes, (ii) methodological: differences in study design, risk of bias and (iii) statistical: variation in
intervention effects or results [188]. Looking deeper into the generated forest plots we concluded the
cause of heterogeneity to be clinical and/or statistical. This is mainly because most of the flavonoids
in a single subgroup are from the same study hence methodological heterogeneity was excluded.
This was further supported by the fact that no single flavonoid was found to solely contribute to
the heterogeneity when applying the leave-one-out strategy in the sensitivity analysis. In that case,
heterogeneity is mainly due to the different flavonoids used in the study (variation in interventions) in
addition to other factors like variable outcomes (number of blood vessels). This clinical heterogeneity
can lead to a statistical heterogeneity manifested as a variation among the effects or results (ratio of
means of number of blood vessels).
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4. Materials and Methods
This review and meta-analysis were conducted according to Preferred Reporting Items for
systematic reviews and Meta Analyses (PRISMA) guidelines [189].
4.1. Search Strategy
For Section 1, a literature search was conducted using ScienceDirect, PubMed and Web of Science
databases between 3 April 2020 and 23 April 2020 with no time limits. The first set of keywords,
(flavonoid, flavone, flavonol, flavanol, anthocyanidin, polyphenol) was combined systematically
using the Boolean operator AND with the second set, (angiogenesis, antiangiogenic, proangiogenic,
“cell migration”, “wound healing”) in all databases (Table S5).
With regards to the detailed meta-analysis for Section 2, the literature search was carried out
using ScienceDirect, PubMed, Web of Science and Google Scholar databases between 8 June 2020 and
10 June 2020 with no time limits. The first set of keywords, (flavonoid, flavone, flavonol, flavanol,
anthocyanidin, polyphenol) was combined systematically using the Boolean operator AND with the
second set, (angiogenesis, “chick chorioallantoic membrane”, “in vivo angiogenesis”) in all databases
(Table S6).
4.2. Inclusion and Exclusion Criteria
Studies were included in the Section 1 overview search if they met the following eligibility criteria:
(i) natural or synthetic flavonoids (ii) in vitro, in vivo and/or ex vivo angiogenesis assays (iii) focus
on cancer, diabetes, bone regeneration or eye diseases. For the meta-analysis Section 2, the inclusion
criteria were: (i) natural or synthetic flavonoids (ii) in vivo CAM angiogenesis assays. Articles not
written in English and/or focusing on chalcones, plant extracts/total flavonoids content, combination
of compounds, nanoformulations, prodrugs, neurological disorders or cardiovascular diseases were
excluded from both searches. This systematic review and meta-analysis followed PRISMA guidelines
(Table S7).
4.3. Data Extraction
Initially, articles’ titles and abstracts were screened based on relevance and inclusion/exclusion
criteria. Full texts were checked in some cases when abstracts failed to provide a detailed description.
Eligible articles were retrieved and data extracted into a specially designed form. The first set of
extracted data for Section 1 included title, publication type, year of publication, flavonoid, disease
of focus and conducted in vitro and/or in/ex vivo angiogenesis assays. The second set of data were
extracted for the meta-analysis Section 2 study and included title, year of publication, flavonoid,
angiogenesis promotor, cancer cell line, concentration, time and duration of flavonoid treatment, results
representation and number of CAMs used for each test concentration (n).
4.4. Data Analysis
Means of the number of blood vessels in a CAM relative to control were used as the outcome
measure. Concentrations were reported in µM in all analyses except for analysis of wogonoside’s
antiangiogenic effect on breast cancer cell lines in which ng/CAM was used. Values are represented as
means ratio ± standard error of means (SEM). For studies reporting standard deviation (SD), the SEM
was calculated by dividing SD by square root of the corresponding study sample size. Pool effect size
was expressed as means ratio and 95% CI and was calculated using the inverse variance (IV) method.
The random effects model was used because it accounts for between study variability. Heterogeneity
was assessed using Higgins’ I2 measure where I2 ≥ 50% indicates substantial heterogeneity [190].
Sensitivity analysis was applied to evaluate the effect of each flavonoid on summary effect size and
on heterogeneity. It is based on the sequential removal of one study at a time. Statistical analysis
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was performed using Review Manager Version 5.1 (The Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen, Denmark) and Microsoft Excel 2016.
5. Conclusions
Despite the promising antiangiogenic activity of flavonoids presented in many literature studies,
no flavonoids have reached clinical trials for this application. This systematic review and meta-analysis
therefore aimed to provide further insight into this area by evaluating the in vivo antiangiogenic activity
of flavonoids as determined by the widely reported, clinically relevant CAM assay. A comprehensive
overview of the antiangiogenic activities of flavonoids with regards to the class of flavonoids, pathology
and assays used was presented. Results have shown that the biggest fraction of studies focused
on the flavone subclass, cancer related angiogenesis, and in vitro assays. Furthermore, an overall
evaluation of the in vivo antiangiogenic activity of flavonoids was offered focusing on SAR and
mechanistic considerations. Isoflavones, flavonols and flavones were found to be the most active
classes of flavonoids where antiangiogenic activity was dose dependent. Several structural features
were considered, from which it was concluded that the position of the hydroxyl substituents and the
degree of unsaturation are key for high activity. Even though there were some limitations such as
the miscellany of the studied flavonoids and the high heterogeneity, this study provided substantial
information that will underpin further investigations by addressing current gaps in the literature
regarding the antiangiogenic activity of flavonoids, and highlighting their future prospective as
potentially clinically active antiangiogenic agents.
Supplementary Materials: The following are available online, Table S1: Study characteristics of Section 1,
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